Skip to main content
MED
NYSE Manufacturing

Steamboat Capital's Parsa Kiai Discloses 8.6% Medifast Stake After $10.5M Accumulation

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Industrial
Sentiment info
Positive
Importance info
7
Price
$11.72
Mkt Cap
$131.06M
52W Low
$9.22
52W High
$13.63
52W Position info
27% above low
Off High info
14% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

MED sits 27% above its 52-week low of $9.22.

Summary

Steamboat Capital and Parsa Kiai disclosed an 8.6% Medifast stake — 963,286 shares bought for about $10.5 million — after a steady run of open-market purchases, including 100,000 shares on November 19.


Key Events · Ownership and Investor Activity · MED

  • 8.6% Stake Disclosed in 13D/A

    In Amendment No. 2 to their Schedule 13D, Steamboat Capital Partners, LLC and Parsa Kiai report beneficial ownership of 963,286 Medifast shares, equal to 8.6% of the class.

  • Roughly $10.5M Accumulated

    Clients of the investment adviser acquired the reported shares in open-market purchases at an aggregate price of approximately $10,463,681, excluding commissions.

  • 100,000 Shares Bought November 19

    The 60-day transaction table shows 100,000 shares purchased on 11/19/2026 at a weighted average of $12.0464 (range $11.855-$12.15), plus 10,436 shares on 11/18 at $12.1613 and 6,480 on 10/28 at $12.2417.

  • Buying Through a Restructuring

    The accumulation follows Q3 2026 revenue of $72.0 million, down 19.4%, and a $17.5 million net loss that included a $15.4 million restructuring charge.


Analysis · MED · Manufacturing

A disclosed 8.6% block with a documented buying pattern puts a large, motivated shareholder on the register — and that is what Parsa Kiai and Steamboat Capital now report: beneficial ownership of 963,286 Medifast shares, or 8.6% of the class, accumulated at an aggregate cost of roughly $10.5 million. The 13D/A formalizes an activist-style position built through repeated open-market buying — 6,480 shares on October 28, 661 on November 6, 10,436 on November 18 and 100,000 on November 19 at a weighted average of $12.0464 — while the company works through a restructuring and a 19.4% revenue decline. Such a stake can pressure management on capital allocation and strategy. The filing itself reports no agreement, board seat or stated intent beyond open-market purchases.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MED was trading at $11.72 on NYSE in the Manufacturing sector, with a market capitalization of approximately $131.1M. The 52-week trading range was $9.22 to $13.63. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MED - Latest Insights

MED
Nov 20, 2026, 2:44 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $11.48
Real-time Price: $11.77 info
Change: +$0.295 (+3%) info
Market Cap: $131.06M info
MED
Oct 26, 2026, 8:05 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $11.87
Real-time Price: $11.77 info
Change: -$0.100 (-0.84%) info
Market Cap: $131.06M info
MED
Aug 28, 2026, 12:47 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $11.95
Real-time Price: $11.77 info
Change: -$0.180 (-2%) info
Market Cap: $131.06M info
MED
Aug 21, 2026, 4:01 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $11.95
Real-time Price: $11.77 info
Change: -$0.180 (-2%) info
Market Cap: $131.06M info
MED
Aug 21, 2026, 12:35 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $11.56
Real-time Price: $11.77 info
Change: +$0.210 (+2%) info
Market Cap: $131.06M info